Oct 19, 2020

Veramaris Pets expands market potential with FDA’s GRAS approval

Veramaris® Pets has been given the go-ahead to sell its natural marine algal oil, rich in EPA & DHA Omega-3, feed ingredient in all fifty US States.

The Veramaris® Pets ingredient, Marine microalgae oil, had been the subject of an Animal GRAS notification which has now been evaluated by the FDA. Following this process, it has received a Letter of “No Questions” from the FDA’s Center of Veterinary Medicine’s Division of Animal Feeds.

This means that customers may now incorporate the product into dog food. Veramaris® Pets Algal Oil is a new source of Omega-3 for pet food which naturally provides two to five times more EPA & DHA Omega-3 fatty acids compared to fish oil. In fact, one kg of the Veramaris oil helps preserve 60 kg of wild fish needed for an equal amount of EPA & DHA. Pet Food Brands can become sustainable and reduce their marine footprint to significantly contribute to UN’s important Sustainable Development Goals.

Commenting on the news, Veramaris’ Jeff Alix, Global Head of Business Development for Companion Animals said: “We are delighted to have received this latest approval. It could only happen because of the time and energy devoted by our people and the significant financial investment from the business. This was a major undertaking and underlines the commitment of Veramaris in this very important market.

“Not only is Veramaris® Pets sustainable, it also provides a concentration of EPA & DHA Omega-3 exceeding 50% and can be used in dog foods that are sold across the U.S.”

Veramaris® Pets is the first of its kind in pet food; a natural, rich and sustainable alternative to fish oil. It helps pets enjoy long, healthy and happy lives. This natural marine algal oil is made from microalgae, grown in a U.S. waste-free production facility, proven to contribute to the health of both pets and our oceans. 

To find out more about Veramaris® Pets, visit: pets.veramaris.com.


Images for download





Veramaris Media contacts

Johan Brouwer

Images for download

Follow us on

About Veramaris

Veramaris, headquartered in Delft, The Netherlands, is a joint venture between DSM and Evonik, both world leaders in science and specialty chemicals. Established in 2018, Veramaris was formed to help realise a vision to conserve natural marine life by using the ocean's own resource, natural marine algae, to sustainably expand the world's access to Omega-3.

Veramaris extracts oil from natural marine algae, rich in both the essential Omega-3 fatty acids EPA & DHA, and also ARA, a long chain Omega-6, vital nutrients for improved brain, heart and eye health in both animals and humans.

The zero-waste industrial scale production process runs at a state-of-the-art site in Blair, Nebraska, USA.

Veramaris enables key stakeholders in aquaculture and pet nutrition to become independent of wild-caught fish and meet the growing demand for sustainable seafood and animal protein.

Legal Disclaimer

This information and any recommendations, technical or otherwise, are presented in good faith and believed to be correct as of the date prepared. Recipients of this information and recommendations must make their own determination as to its suitability for their purposes. VERAMARIS EXPRESSLY DISCLAIMS ANY REPRESENTATIONS AND WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, AS TO THE ACCURACY, RELIABILITY, COMPLETENESS, NON-INFRINGEMENT, MERCHANTABILITY AND/OR FITNESS FOR A PARTICULAR PURPOSE (EVEN IF VERAMARIS IS AWARE OF SUCH PURPOSE) WITH RESPECT TO ANY INFORMATION AND RECOMMENDATIONS PROVIDED. IN NO EVENT SHALL VERAMARIS BE LIABLE FOR ANY DAMAGES ARISING FROM OR RELIANCE UPON, OR USE OF, ANY INFORMATION OR RECOMMENDATIONS PROVIDED HEREIN. Reference to any trade names used by other companies is neither a recommendation nor an endorsement of the corresponding product and does not imply that similar products could not be used. Veramaris reserves the right to make any changes to the information and/or recommendations at any time, without prior or subsequent notice.

Go back

Newsroom overview